Genital Warts, Vulvar Intraepithelial Neoplasia
Conditions
Keywords
condyloma acuminate, ano-genital warts, genital warts, cutaneous condyloma, Vulva pre-cancerous lesions, Vulvar Intraepitheral Neoplasia, VIN, EGW
Brief summary
This pilot clinical study is to evaluate the efficacy & safety of SR-T100 gel (2.3% of SM in Solanum undatum plant extract) in patients with VIN(s) or EGW(s).
Detailed description
An open-label, pilot study to evaluate the efficacy & safety profiles of SR-T100 gel in treating patients with VINs or EGWs. Male & female older than 20 years old have at least one VIN or EGW with lesion size greater than 5 mm in diameter are candidates for this study. The primary endpoint is evaluated based on patients who has received 16-week treatment and presents evaluable measurement datas by the end of 20th week. The secondary endpoints will be evaluated based on all patients with measurable values for VINs or EGWs, recruited patients in this study has never had experiencs associated with prior SR-T100 treatment of any sorts during their life time before becoming a participant in this study. The study plans to recruit 20 patients with VINs or EGWs, the enrollment duration will last two years with total of 40 patients involved.
Interventions
DRUGSR-T100 gel with 2.3% of SM in Solanum undatum plant extract
Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon & before bed time. Medication should be reapply after bathing or cleaning.
Sponsors
G&E Herbal Biotechnology Co., LTD
National Cheng-Kung University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(EGW group)Inclusion Criteria: * Male & female patients older than 20 years old presents at least one pathologically confirmed with histopathology EGW with lesion size greater than 5mm in diameter. (EGW group)
Exclusion criteria
* Patients with invasive neoplasia, enlarged lymph nodes invasive squamous cell carcinoma, having treated with other investigational drugs within 30 days, pregnancy & lactating females, female with pregnancy potential without using effective boundary barrier or patients with immune-deficience. (VIN group)Inclusion Criteria: * Female patients older than 20 years old presents at least one histopathologically confirmed VIN with lesion size greater than 5mm in diameter. (VIN group)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients achieve greater than or equal to 75% lesion size reduction | 20 weeks (16 weeks treatment period + 4 weeks follow-up period) | Proportion of patients achieving greater than or equivalent to 75% lesion size reduction from baseline on the 20th week after 16 weeks of SR-T100 gel treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total clearance rate | 20 weeks (16 weeks treatment period + 4 weeks follow-up period) | Proportions of patient with treated VIN(s) or EGW(s) completely eradicate. |
| Partial clearance rate | 20 weeks (16weeks treatment period + 4 weeks follow-up period | Proportions of patient with treated VIN(s) or EGW(s) size reduction is greater than 75% in volume from baseline. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety | 16 weeks | To evaluate safety profile of SR-T100 gel by adverse events, serious adverse events, PEs, vital signs & laboratory data changes. |
Countries
Taiwan
Outcome results
None listed